KR101314460B1 - Ｒｇｄ-함유 펩티드의 방사성 표지된 접합체 및클릭-화학을 통한 그의 제조 방법 - Google Patents

Ｒｇｄ-함유 펩티드의 방사성 표지된 접합체 및클릭-화학을 통한 그의 제조 방법 Download PDF

Info

Publication number
KR101314460B1
KR101314460B1 KR1020077014048A KR20077014048A KR101314460B1 KR 101314460 B1 KR101314460 B1 KR 101314460B1 KR 1020077014048 A KR1020077014048 A KR 1020077014048A KR 20077014048 A KR20077014048 A KR 20077014048A KR 101314460 B1 KR101314460 B1 KR 101314460B1
Authority
KR
South Korea
Prior art keywords
formula
compound
vector
peptide
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077014048A
Other languages
English (en)
Korean (ko)
Other versions
KR20070091626A (ko
Inventor
에릭 아르스타드
마티아스 에버하르트 글레이저
Original Assignee
해머스미쓰 이마네트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 해머스미쓰 이마네트 리미티드 filed Critical 해머스미쓰 이마네트 리미티드
Publication of KR20070091626A publication Critical patent/KR20070091626A/ko
Application granted granted Critical
Publication of KR101314460B1 publication Critical patent/KR101314460B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
KR1020077014048A 2004-12-22 2005-12-09 Ｒｇｄ-함유 펩티드의 방사성 표지된 접합체 및클릭-화학을 통한 그의 제조 방법 Expired - Fee Related KR101314460B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0428012.9A GB0428012D0 (en) 2004-12-22 2004-12-22 Radiolabelling methods
GB0428012.9 2004-12-22
PCT/GB2005/004729 WO2006067376A2 (en) 2004-12-22 2005-12-09 Radiolabelled conjugates of rgd-containing peptides and methods for their preparation via click-chemistry

Publications (2)

Publication Number Publication Date
KR20070091626A KR20070091626A (ko) 2007-09-11
KR101314460B1 true KR101314460B1 (ko) 2013-10-10

Family

ID=34112991

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077014048A Expired - Fee Related KR101314460B1 (ko) 2004-12-22 2005-12-09 Ｒｇｄ-함유 펩티드의 방사성 표지된 접합체 및클릭-화학을 통한 그의 제조 방법

Country Status (13)

Country Link
US (2) US7972588B2 (enExample)
EP (4) EP2275145A1 (enExample)
JP (2) JP5743372B2 (enExample)
KR (1) KR101314460B1 (enExample)
CN (2) CN101084020A (enExample)
AU (1) AU2005317903C1 (enExample)
BR (1) BRPI0519317A2 (enExample)
CA (2) CA2589136C (enExample)
GB (1) GB0428012D0 (enExample)
MX (1) MX2007007560A (enExample)
NO (1) NO341638B1 (enExample)
RU (1) RU2419627C2 (enExample)
WO (1) WO2006067376A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071718B2 (en) 2004-12-22 2011-12-06 General Electric Company Selective radiolabeling of biomolecules
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
EP2029616A1 (en) * 2006-06-21 2009-03-04 Hammersmith Imanet Limited Chemical methods and apparatus
EP2029179A2 (en) 2006-06-21 2009-03-04 Hammersmith Imanet, Ltd Radiolabelling methods
JP2010502585A (ja) * 2006-08-28 2010-01-28 ジーイー・ヘルスケア・リミテッド ６８Ｇａ標識ペプチド系放射性医薬品
WO2008025886A1 (en) * 2006-09-01 2008-03-06 Wallac Oy Metal chelates and chelating agents containing triazolyl subunits
US8652440B2 (en) * 2007-05-10 2014-02-18 The Trustees Of Columbia University In The City Of New York Methods for diagnosing diseases and evaluating treatments therefor using PET
CN101903047B (zh) * 2007-12-20 2015-10-21 通用电气公司 生物分子的选择性放射性标记
EP2147684A1 (en) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
GB0815831D0 (en) * 2008-09-01 2008-10-08 Imp Innovations Ltd Compounds
US8961930B2 (en) 2008-09-05 2015-02-24 Imperial Innovations Limited Isatin derivatives for use as in vivo imaging agents
PL2346870T3 (pl) * 2008-10-10 2016-01-29 Merck & Cie Foliany znakowane fluorem-18 jako radioznaczniki pet
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
EP2210882A1 (en) * 2009-01-16 2010-07-28 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Synthesis of new protected azahistidine, their processes and their use in synthesises
WO2010099273A1 (en) * 2009-02-27 2010-09-02 Genentech, Inc. Methods and compositions for protein labelling
US8722014B2 (en) * 2009-05-01 2014-05-13 Washington University 1 H-[1, 2, 3] triazole substituted amino acids and uses thereof
GB0914543D0 (en) 2009-08-20 2009-09-30 Ge Healthcare Ltd Radioiodination method
EP2498826A1 (en) * 2009-11-11 2012-09-19 NeuroSearch AS Labelled pyrrolyl-oxadiazolyl-diazabicyclononane derivatives and their use in diagnostic methods
GB0921573D0 (en) * 2009-12-10 2010-01-27 Ge Healthcare Ltd Iodine radiolabelling method
GB0922304D0 (en) 2009-12-22 2010-02-03 Ge Healthcare Ltd Radioiodinated compounds
AU2010336357B2 (en) * 2009-12-23 2015-04-16 Board Of Regents Of The University Of Nebraska Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer
US9517279B2 (en) * 2010-04-14 2016-12-13 The Mclean Hospital Corporation 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof
US9770515B2 (en) 2010-06-01 2017-09-26 Advanced Proteome Therapeutics Inc. Crosslinking of proteins and other entities via conjugates of α-haloacetophenones, benzyl halides, quinones, and their derivatives
EP2595967B1 (en) * 2010-07-23 2016-03-23 University Of Delaware Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes
GB201014023D0 (en) * 2010-08-20 2010-10-06 Ucl Business Plc Process for producing bioconjugates and products thereof
WO2012074840A2 (en) 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
GB201019824D0 (en) 2010-11-23 2011-01-05 Ge Healthcare Ltd Radioiodination method
GB201021369D0 (en) 2010-12-16 2011-01-26 Ge Healthcare Ltd Radioiodinated fatty acids
GB201021517D0 (en) * 2010-12-20 2011-02-02 Ge Healthcare Ltd Radioiodinated guanidines
CN103402550B (zh) 2010-12-22 2015-12-09 通用电气健康护理有限公司 用含有18f的有机硅化合物标记的her2结合肽
SG191292A1 (en) 2010-12-22 2013-07-31 Gen Electric Radiolabled her2 binding peptides
CA2828810A1 (en) 2011-03-01 2012-09-07 Ge Healthcare Limited Radiolabelled octreotate analogues as pet tracers
US20120251448A1 (en) * 2011-03-03 2012-10-04 Hefti Franz F Compounds for Use in the Detection of Neurodegenerative Diseases
US9023318B2 (en) * 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
WO2013048832A1 (en) 2011-09-29 2013-04-04 Ge Healthcare Limited 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells
WO2013048811A1 (en) 2011-09-30 2013-04-04 Ge Healthcare Limited Imaging and radiotherapy methods for tumour stem cells
WO2013082508A1 (en) * 2011-12-02 2013-06-06 The Regents Of The University Of Michigan Compositions and methods for the treatment and analysis of neurological disorders
GB201121911D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Radiofluorination method
WO2013113680A1 (en) * 2012-02-03 2013-08-08 Aarhus Universitet Radiolabeled bile acids and bile acid derivatives
EP2657213A1 (en) * 2012-04-24 2013-10-30 Institut National de la Santé et de la Recherche Medicale Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors
US20140065070A1 (en) * 2012-08-28 2014-03-06 Mcmaster University Methods of preparing triazole-containing radioiodinated compounds
WO2014065413A1 (ja) * 2012-10-26 2014-05-01 日本たばこ産業株式会社 トリアゾール・イソオキサゾール化合物およびその医薬用途
US20150023877A1 (en) * 2013-07-18 2015-01-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of parkinsons disease diagnosis and monitoring treatment
ES2700348T3 (es) * 2014-01-05 2019-02-15 Univ Washington Trazadores radioetiquetados para poli (ADP-ribosa) polimerasa-1 (PARP-1), métodos y usos para estos
US20160022846A1 (en) * 2014-07-22 2016-01-28 Ge Healthcare Limited Iodine radiolabelling method
MD3310816T2 (ro) * 2015-06-19 2021-01-31 Eisai R&D Man Co Ltd Imunoglobuline conjugate Cys80
WO2017023999A1 (en) * 2015-08-03 2017-02-09 Emory University Methylsulfonamide derivatives and uses related thereto
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
JP7554178B2 (ja) * 2018-07-26 2024-09-19 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド イメージングのための組成物および方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006491A2 (en) 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors
WO2004055160A2 (en) * 2002-12-13 2004-07-01 The Trustees Of Columbia University In The City Of New York Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry
WO2005003294A2 (en) * 2003-06-18 2005-01-13 The Scripps Research Institute Unnatural reactive amino acid genetic code additions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4913891A (en) * 1986-04-17 1990-04-03 The United States Of America As Represented By The United States Department Of Energy Positron emitter labeled enzyme inhibitors
WO2001072714A2 (en) * 2000-03-24 2001-10-04 Euro-Celtique S.A. Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker
US6350360B1 (en) 2000-04-07 2002-02-26 Sandia Coroporation Method of fabricating a 3-dimensional tool master
NZ521735A (en) * 2000-04-12 2004-12-24 Amersham Health As Peptide-based compounds, their use as targeting vectors that bind to receptors associated with antiogenesis such as integrin receptors
GB0115927D0 (en) * 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
ATE469135T1 (de) 2002-05-30 2010-06-15 Scripps Research Inst Kupferkatalysierte ligierung von aziden und acetylenen
MXPA05011127A (es) * 2003-04-17 2006-03-10 Scripps Research Inst Expansion del codigo genetico eucariontico.
NO20033115D0 (no) 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
CN101035565A (zh) * 2004-10-07 2007-09-12 皇家飞利浦电子股份有限公司 用于医学显像的化合物、试剂盒和方法
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006491A2 (en) 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors
WO2004055160A2 (en) * 2002-12-13 2004-07-01 The Trustees Of Columbia University In The City Of New York Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry
WO2005003294A2 (en) * 2003-06-18 2005-01-13 The Scripps Research Institute Unnatural reactive amino acid genetic code additions

Also Published As

Publication number Publication date
RU2007122804A (ru) 2009-01-27
CA2817636A1 (en) 2006-06-29
US8679455B2 (en) 2014-03-25
CN105012972A (zh) 2015-11-04
US7972588B2 (en) 2011-07-05
JP2012254998A (ja) 2012-12-27
RU2419627C2 (ru) 2011-05-27
CA2589136A1 (en) 2006-06-29
EP2275145A1 (en) 2011-01-19
JP5743372B2 (ja) 2015-07-01
AU2005317903B8 (en) 2012-01-19
EP1830890A2 (en) 2007-09-12
JP2008528445A (ja) 2008-07-31
AU2005317903B2 (en) 2011-12-01
KR20070091626A (ko) 2007-09-11
WO2006067376A3 (en) 2007-07-26
BRPI0519317A2 (pt) 2009-01-13
AU2005317903A1 (en) 2006-06-29
US20090311177A1 (en) 2009-12-17
EP2266629B1 (en) 2015-12-09
MX2007007560A (es) 2007-11-21
CN101084020A (zh) 2007-12-05
NO341638B1 (no) 2017-12-18
WO2006067376A2 (en) 2006-06-29
CA2589136C (en) 2015-10-06
NO20073157L (no) 2007-06-20
GB0428012D0 (en) 2005-01-26
US20110236311A1 (en) 2011-09-29
AU2005317903C1 (en) 2012-05-10
EP2266629A1 (en) 2010-12-29
EP2258403A1 (en) 2010-12-08

Similar Documents

Publication Publication Date Title
KR101314460B1 (ko) Ｒｇｄ-함유 펩티드의 방사성 표지된 접합체 및클릭-화학을 통한 그의 제조 방법
US8409547B2 (en) Radiolabelling methods
EP2680889B1 (en) Radiolabelled octreotate analogues as pet tracers
US20100034740A1 (en) Radiofluorination methods
KR20100022987A (ko) 표지 방법
AU2011250795A1 (en) Radiolabelling methods
CN113557037A (zh) 用于核医学和放射引导医学的诊断/治疗用途的放射性药物
HK1136587A (en) Chemical methods and apparatus
HK1087928B (en) Methods of radiofluorination of biologically active vectors
HK1087928A1 (zh) 生物活性载体的放射氟化方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160927

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160927